Current treatments for intestinal diseases including inflammatory bowel diseases, irritable
bowel syndrome, and colonic bacterial infections are typically small molecule oral dosage …

Teduglutide has been described as an effective treatment for parenteral support (PS)
reduction in patients with short bowel syndrome (SBS). However, a quantitative summary of …

Intestinal failure, following extensive anatomical or functional loss of small intestine, has
debilitating long-term consequences for children. The priority of patient care is to increase …

Background & aims In 2016, ESPEN published the guideline for Chronic Intestinal Failure
(CIF) in adults. An updated version of ESPEN guidelines on CIF due to benign disease in …

Background This study evaluated the safety and efficacy of teduglutide in pediatric patients
with short bowel syndrome–associated intestinal failure (SBS‐IF). Methods A 24‐week …

Objectives To assess the natural history and outcomes of children with intestinal failure in a
large, multicenter, geographically diverse contemporary cohort (2010-2015) from 6 pediatric …

Abstract Purpose of Review Although Glucagon-like peptide (GLP)-1 receptor agonists have
been used for almost two decades in the treatment of diabetes mellitus type 2 and, lately, in …

Objectives: The aim of the study was to describe the experience with teduglutide of several
Spanish hospitals in pediatric patients with SBS (SBS). Methods: Seventeen pediatric …

Background & aims Teduglutide, a GLP-2-analog, has proven effective in two placebo-
controlled studies in reducing parenteral support (PS) in patients with short bowel syndrome …

Background & aims Teduglutide, a glucagon-like peptide 2 (GLP-2) analog, is an approved
medication specific for short bowel syndrome patients with chronic intestinal failure (SBS-IF) …